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Human tissues samples were obtained from Royal Prince Alfred Hospital,
142
Sydney with approval of Human Research Ethics Committee (X10-0072).
143
Human tissue used in this study was previously utilized for research (12, 15) .
144
Informed written consent was obtained from all participants. The ethics 145 committee waived the need for written consent for use of donor tissue. In 
225
Significance was accepted at p<0.05. Data is shown as mean ± SEM. As 
242
We have previously observed higher CD147 expression in primary biliary 243 cholangitis (PBC), primary sclerosing cholangitis (PSC) and hepatitis C virus 244 (HCV)-induced liver injury in patients (12, 54) . We chose to investigate the 245 expression of CD147 in a TAA-induced mouse model of liver injury to further 246 establish the source and function of CD147 in liver injury. During the 247 development of TAA-induced liver injury we observed a progressive increase 248 in the expression of CD147 mRNA in whole liver tissue ( Fig 1A) . When 249 hepatocytes and leukocytes were analysed separately a significant increase of 250 CD147 mRNA expression was observed in leukocytes (30-fold) ( Fig 1B) .
251
Minimal CD147 upregulation was observed on hepatocytes ( Fig 1B) . This data
252
shows that CD147 expression is upregulated in a mouse model of liver injury 253 and CD147 predominantly increased on leukocytes, not hepatocytes following 254 injury. Further, we examined leukocyte CD147 expression in blood, liver and 255 spleen showing a shift from control to 20 weeks in circulating and intrahepatic 256 leukocytes ( Fig 1C) . increased on all liver leukocytes, with peak expression at 8 weeks of injury.
277
Interestingly, as liver injury progressed, we observed a significant loss of NKT 278 cells and macrophages and a significant increase of CD8 + T cells, eosinophils 279 and neutrophils from the liver.
281
To establish whether similar CD147 expression patterns were occurring in an 282 extrahepatic lymphoid organ, the spleen was also analysed by flow cytometry 283 in the same manner described above. This trend was true for all sub- 
308
To determine how lymphocytes localized during chronic liver injury, CD45
309 staining was conducted on a range of injury models including TAA treatment in 310 C57Bl/6, CCl 4 in C57Bl/6 and CCl 4 in balb/c mice (Fig 3) . In uninjured control 311 livers, lymphocytes dispersed evenly within the liver tissue ( Fig 3A) . In contrast,
312
in both TAA ( Fig 3B) and CCl 4 ( Fig 3C) injury models not only were total CD45 313 cells increased ( Fig 3D) but CD45 cells were found to aggregate (defined as >5
314
CD45 + cells in contact). Importantly the majority of aggregation occurred 315 around portal triads where fibrosis first appears. Peak infiltrate was observed 316 after 8 weeks of TAA and 4 weeks of CCl 4 , which correlated with peak immune 317 cell aggregation ( Fig 3E) . Thus, injury is shown to induce increased immune 318 infiltrate and increased immune cell aggregation.
320
Apoptosis and proliferation within aggregates was assessed by cleaved 321 caspase-3 and Ki-67, respectively (Supplemental Figure 1) . This was 322 assessed in both normal and injured liver tissue. In C57Bl/6 mice after 4 323 weeks of CCl 4 administration compared to untreated animals, apoptosis went 324 from being most undetected to occasionally seen, which was a significant 325 increase (p = 0.05), but no significant change in proliferation was seen (p = 326 0.08). This is consistent with other publications (55, 56) . 
342
To confirm that immune cell expression of CD147 and immune cell aggregation 343 was not exclusive to mouse models we examined human liver tissue from 344 healthy donors ( Fig 4A) and patients with PSC, alcohol induced liver damage 345 (EtOH), AIH and HCV ( Fig 4B) . Interestingly we not only observed CD147 346 expression on hepatocytes but all CD45 + immune cells expressed CD147 in 347 both healthy and injured livers. Total CD45+ immune cells were significantly 348 increased in diseased liver, irrespective of whether disease was immune 349 mediated (AIH, PSC, HCV) or not (EtOH) (Fig 4C) . Inflammatory cells were 350 shown to aggregate with liver injury ( Fig 4B) and significantly more immune 
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To determine if CD147 was important for the formation of immune cell 373 aggregates the effects of anti-CD147 intervention were studied in CCl 4 374 induced liver injury in both C57Bl/6 and balb/c mice. Anti-CD147 did not significantly reduce the number of CD45 + cells in the liver (Fig 5E, F) . The
376
percentage of immune cells that formed immune cell aggregation was 377 reduced with anti-CD147 intervention in both mouse backgrounds (Fig 5G, H) .
378
In C57Bl6 there was non-significant, less than 1.5-fold, increase in ALT with 379 injury and no significant change was seen with anti-CD147 intervention (Fig   380  5I) . However, in balb/c mice with more significant injury the reduction in 381 immune cell aggregation correlated with as significantly reduced serum ALT 382 levels ( Fig 5J) . Thus, CD147 inhibition appeared to significantly reduce the 383 formation of immune cell aggregates and reduce significant liver injury. Specific leukocyte subsets within aggregates.
405
We have just shown that anti-CD147 intervention reduces the percentage of aggregates during liver injury ( Fig 6) . After anti-CD147 treatment, we observed 412 a decrease in the number of aggregates with at least one F4/80+, B220+ and 413 CD3+ cell. The number of Gr-1+ cells in aggregates was not altered after anti-
414
CD147 treatment (Fig 6) . Thus, anti-CD147 intervention was shown to target 415 specific cells reducing immune cell aggregation. This study has demonstrated that with progressive inflammation-430 associated tissue injury, immune cells cluster and contribute directly to the 431 magnitude of the injury. Our novel discovery is that with liver injury CD147 is 432 increased on the surface of leukocytes and then mediates cell-cell aggregation 433 that determines the extent of liver injury. However, if we blocked CD147 with a 434 mAb then CD45 + cell numbers in the liver remain unchanged but leukocytes 435 are no longer found in aggregates. Importantly, we have already reported there 436 is a significant reduction in liver injury seen with anti-CD147 mAb (15) . Further, 437 CD147 mediated leukocyte aggregation appears to cause or significantly 438 exacerbate injury as aggregate formation proceeds the development of 439 significant fibrosis (15) . Therefore, this is not just a reduction in aggregation and 440 inflammatory markers (AST/ALT) but also a reduction in resultant fibrosis.
441
All intrahepatic leukocyte subpopulations (CD4 + , CD8 + , NK, B-cell and 442 macrophages) rapidly increase CD147 surface protein and total mRNA 14 443 expression with liver injury. Therefore, this data shows that following liver injury,
444
circulating and intrahepatic leukocytes increase CD147 expression.
445
Subsequently, it has been shown leukocytes undergo activation (57) ,
446
aggregations are formed and then contribute to injury. It is unknown if leukocyte 447 activation occours concurrent or prior to aggregation. The recruitment of 448 inflammatory cells from the periphery to sites of liver injury is important in the 449 pathogenesis of liver injury (57) but its relationship to aggregation and 450 dependence on CD147 expression was unrecognised. Based on these results
451
CD147 is likely pivotal the development of inflammation in liver injury partly 452 through the previously unrecognized role in leukocyte aggregate formation.
453
In liver injury anti-CD147 intervention leads to a reduction in immune cell 454 aggregation characterised by a reduction in serum transaminases and total 455 tissue MMP activity (15) . Importantly, there is no significant change in the total 456 number of CD45+ cells infiltrating the liver. This suggests that the cells are not 457 proliferating to form clusters but rather they aggregate with injury. Further, we 458 have shown that the clusters that diminish with anti-CD147 intervention in injury 459 contain B-cells (B220/CD19) and macrophages/Kupffer cells (F480).
460 Importantly, the isotype antibody controls have the same phenotype as wild-461 type animals. Importantly, we have shown these leukocyte clusters form in 462 progressive human liver injury irrespective cause.
463
CD147 has a number of binding interactions. The CD147 binding 464 partners; α3β1, α6β1, CD44, LFA-1, ICAM-1, sydnedcan-1 and hyaluronan all 465 have known roles in immune cell retention at sites of inflammation. The 466 functional significance of CD147 protein binding interactions in the aggregation 467 phenotype is unknown, likely to be pivotal and clearly needs to be determined.
468
Multiple proteins are known membrane-binding partners of CD147 (see
469
Background) (29, 30, (38) (39) (40) . Further, many of the CD147 complex proteins are 470 found on leukocytes and/or have known roles in leukocyte retention at sites of 471 inflammation (including CD98 (38) , 1-integrin (38) , CD43 (58) , LFA-1 (28, 43, 58) , ICAM-472 1 (43) , sydnecan-1 (28, 58) , and hyaluronan (39, 59) ). Additionally, CD147 through 473 interactions with CD98 (38, 39) and/or β1-integrin (38) is known to mediate 474 homotypic cell clustering of leukocytes. Therefore, CD98 (38, 39) , 1-integrin (38) , 15 475 LFA-1 (28, 43, 58) and ICAM-1 (43) are the most promising protein binding 476 interactions to study that are likely involved in the aggregation phenotype.
477 Therefore, we have identified CD147 as a potential therapeutic target to 478 minimize exacerbation of liver injury via reduction of leukocyte aggregate 479 accumulations in the liver tissue. Further work is required to determine the role 480 of CD147 in liver fibrogenesis resultant from persistent inflammatory insult. 481 482 483
